Punt CJ - Search Results

1

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.

Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, de Vries IJ, Punt CJ. Lesterhuis WJ, et al. Among authors: punt cj. Cancer Immunol Immunother. 2011 Feb;60(2):249-60. doi: 10.1007/s00262-010-0942-x. Epub 2010 Nov 11. Cancer Immunol Immunother. 2011. PMID: 21069321 Free PMC article. Clinical Trial.

2

Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.

Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, Figdor CG, Adema GJ. Eggert AA, et al. Among authors: punt cj. Cancer Res. 1999 Jul 15;59(14):3340-5. Cancer Res. 1999. PMID: 10416590

3

[Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer].

Punt CJ, de Vries IJ, Mulders PF, Adema GJ, Figdor CG. Punt CJ, et al. Ned Tijdschr Geneeskd. 1999 Nov 27;143(48):2408-14. Ned Tijdschr Geneeskd. 1999. PMID: 10608974 Review. Dutch.

4

Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy.

Schreurs MW, Eggert AA, Punt CJ, Figdor CG, Adema GJ. Schreurs MW, et al. Among authors: punt cj. Crit Rev Oncog. 2000;11(1):1-17. Crit Rev Oncog. 2000. PMID: 10795625 Review.

5

Phenotypical and functional characterization of clinical grade dendritic cells.

de Vries IJ, Eggert AA, Scharenborg NM, Vissers JL, Lesterhuis WJ, Boerman OC, Punt CJ, Adema GJ, Figdor CG. de Vries IJ, et al. Among authors: punt cj. J Immunother. 2002 Sep-Oct;25(5):429-38. doi: 10.1097/00002371-200209000-00007. J Immunother. 2002. PMID: 12218781

6

Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.

De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, Strijk SP, Ruers TJ, Boerman OC, Oyen WJ, Adema GJ, Punt CJ, Figdor CG. De Vries IJ, et al. Among authors: punt cj. Cancer Res. 2003 Jan 1;63(1):12-7. Cancer Res. 2003. PMID: 12517769

7

Analysis of dendritic cell trafficking using EGFP-transgenic mice.

Eggert AA, van der Voort R, Torensma R, Moulin V, Boerman OC, Oyen WJ, Punt CJ, Diepstra H, de Boer AJ, Figdor CG, Adema GJ. Eggert AA, et al. Among authors: punt cj. Immunol Lett. 2003 Oct 9;89(1):17-24. doi: 10.1016/s0165-2478(03)00105-6. Immunol Lett. 2003. PMID: 12946860

8

Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.

de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ. de Vries IJ, et al. Among authors: punt cj. Clin Cancer Res. 2003 Nov 1;9(14):5091-100. Clin Cancer Res. 2003. PMID: 14613986

9

Presence and localization of T-cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells.

Bernsen MR, Diepstra JH, van Mil P, Punt CJ, Figdor CG, van Muijen GN, Adema GJ, Ruiter DJ. Bernsen MR, et al. Among authors: punt cj. J Pathol. 2004 Jan;202(1):70-9. doi: 10.1002/path.1494. J Pathol. 2004. PMID: 14694523

10

Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results.

Lesterhuis WJ, de Vries IJ, Adema GJ, Punt CJ. Lesterhuis WJ, et al. Among authors: punt cj. Ann Oncol. 2004;15 Suppl 4:iv145-51. doi: 10.1093/annonc/mdh919. Ann Oncol. 2004. PMID: 15477299 Free article. Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

485 results

Search Page